ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1343

EARLY Improvements in the Lower Limbs Enthesis by Ultrasound Predicting Later Favorable Responses in TNF Inhibotors-Treated Patients with Spondyloarthritis

Kensuke Kume1, Kanzo Amano1, Kuniki Amano2, Hiroyuki Ohta3 and Noriko Kuwaba4, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Sky Clinic, Hiroshima, Japan, 3Medical Research, hiroshima clinic, Hiroshima, Japan, 4Medical Research, Sanki Clinical Link, Hiroshima, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Spondylarthropathy, tumor necrosis factor (TNF) and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Lower limbs enthesis by ultrasound (US) detects inflammatory activity in patients with spondyloarthritis(SpA) and is a diagnostic tool of early SpA. The present objective was to follow SpA patients starting anti-TNF inhibitors with US and clinical assessments to explore whether any variable in baseline or early stage could predict later favorable responses.

Methods: This study is prospective and US reader and clinical physician blinded study. Patients with SpA starting anti-TNF inhibitors were consecutively included and examined at baseline and, after 1 and 12 weeks with standardized bilateral ultrasound of six enthesis (Madrid sonography enthesitis index (MASEI)). In addition, the patients were assessed clinically with ASDAS, assessor global VAS (study nurse), ESR and CRP. Patients with ASDAS clinical important improvement at the 12 weeks examination was defined as responders. The results of US score (MASEI), clinical and laboratory assessments at baseline and after 1 week were explored by Mann-Whitney tests to examine for associations with the responders.

Results: A total of 45 patients were included (mean (SD) age 60.3 (25.2) years, disease duration14.2 (6) years, and 35% women, with 73% using infliximab and 27% adalimumab).A total of 69 % of the patients were defined as ASDAS responders, and they had significantly lower US score (MASEI) (p=0.03), assessor global VAS (study nurse) (p=0.02), and CRP (p=0.02)at the 12 weeks examination. Baseline US score (MASEI), ASDAS, assessor global VAS, ESR or CRP did not separate between responders and non-responders. At 1 week examination the only variable differing between responders and non-responders was the US score (MASEI), with a significant reduction in US score (MASEI) in the responders versus non-responders 12.6 (5.4) versus 2.3(3.3) (p=0.03).

Conclusion: US enthesis images at 1 week after TNF inhibitors in patients with SpA are useful to identify later good responders.

References: Alcalde M, Acebes JC, Cruz M, et al. A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. Ann Rheum Dis 2007 ; 66 : 1015 – 19 .Machado P, Landewé R, Lie E, Kvien TK et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011 ;70:47-53


Disclosure:

K. Kume,
None;

K. Amano,
None;

K. Amano,
None;

H. Ohta,
None;

N. Kuwaba,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-improvements-in-the-lower-limbs-enthesis-by-ultrasound-predicting-later-favorable-responses-in-tnf-inhibotors-treated-patients-with-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology